BioSpace News Archive

Policy

BIO Calls for Innovation in Addressing the Opioid Crisis

As drugmakers continue to develop an understanding of what pain is to the human body, it helps drive the development of innovative manners to treat it that transcend addictive options such as opioids.

March 8, 2019
·
3 min read
·
Alex Keown
Business

Oxurion NV Business Update – FY 2018

Significant Progress with Novel Diabetic Eye Disease Portfolio

March 8, 2019
·
17 min read
Business

Investment Firm Appaloosa Again Calls for Leadership Changes at Allergan

After Allergan reported that its late-stage adjunctive treatment for major depressive disorder failed to distinguish itself against placebo, hedge fund investor Appaloosa LP is again calling on the Ireland-based company to make some changes to its board of directors, including tapping a new chairman.

March 8, 2019
·
2 min read
·
Alex Keown
Policy

In an Attempt at Clarity, FDA Makes the Biosimilar Naming Convention Even More Confusing

The U.S. Food and Drug Administration (FDA) and some biosimilar and generic drug advocates were concerned that the naming for biosimilars—the branded drug’s name and a unique, four-letter suffix—made the drugs sound inferior to consumers than their branded counterparts.

March 8, 2019
·
4 min read
·
Mark Terry
Biotech Beach

BioSpace Hotbed Report: Hot Takes From Biotech Beach

For anyone who has ever visited San Diego, there is an automatic appeal of the city’s laid-back vibe and incredibly pleasant temperatures.

March 8, 2019
·
4 min read
·
Alex Keown
Business

PureTech’s Independent Affiliate Akili Announces Partnership with Shionogi to Develop and Commercialise Digital Therapeutics in Certain Asian Markets

Akili receives upfront payments totalling $20 million and has the potential to receive milestone payments for Japan and Taiwan commercialisation of up to an additional $105 million, in addition to substantial royalties on product sales

March 8, 2019
·
11 min read
Policy

FDA Advisory Panel Gives Mixed Review to Sanofi’s Dengue Vaccine

Sanofi has been hoping to secure approval from the U.S. Food and Drug Administration for its dengue vaccine, but a mixed review from a panel of experts could sink the chances of a green light for the medication.

March 8, 2019
·
2 min read
·
Alex Keown
Drug Development

LogicBio Plans First Clinical Trial for Gene Editing in Children

Following last year’s stellar initial public offering in October, where it raised $80.5 million, about $10 million over initial expectations, LogicBio Therapeutics is planning a gene-editing clinical trial in children.

March 8, 2019
·
2 min read
·
Mark Terry
Business

TaiwanJ Pharmaceuticals Obtained US$26M Deal for Licensing and Co-Development Contract with Newsoara Biopharma on JKB-122 Asian Rights

TaiwanJ Pharmaceuticals has signed a US$26 million contract with Newsoara Biopharma to license out its drug candidate JKB-122 for further development in Asia.

March 8, 2019
·
3 min read
Biotech Bay

Sangamo Therapeutics Announces Publication Of Data Demonstrating New Zinc Finger Nuclease Architectures Enabling High-Precision Genome Editing

Data published in Nature Communications show new architectures increase targeting capabilities by 64-fold

March 8, 2019
·
4 min read